FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid

Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. Processed through Diagnocine's validated Quadruple-stage filtration system reaching a 0.04 µm final cut-off, FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X LiquidA quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage nano-filtration: 0.1 µm (Prefiltration I & II) + 0.04 µm (Final filtration I & II), reaching a 0.04 µm final cut-off across four sequential passes
• Endotoxin release specification: < 0.05 EU/mL (USP <85> BET, verified per manufacturing batch)
• Low-glucose (1.0 g/L) MEM base formulation, supplied without sodium pyruvate and without phenol red; pH 7.4 (USP <791>)
• Sodium bicarbonate-buffered (2200 mg/L NaHCO₃); requires a 5% CO₂ incubator atmosphere to maintain physiological pH
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm)
• Manufactured under an ISO 13485:2016 quality management system; final packaging, testing and customization at Diagnocine, Totowa, NJ
• Mycoplasma control via 0.1 µm mycoplasma-retentive final-stage filtration (not tested per lot)
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and batch-to-batch endotoxin variation that accumulate inside microchannels — corrupting biosensor readings and shortening device lifetimes. FluxMPS™ is engineered to address these failure modes at the filtration stage.

Quadruple-stage filtration system

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid is processed through a validated four-stage filtration sequence — two dedicated 0.1 µm / 0.04 µm prefilter-and-final-filter pairs run in series — reaching a 0.04 µm final pore size. This removes mycoplasma-sized organisms, subvisible particulates, and bioburden that standard 0.22 µm filtration cannot address.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris and protein aggregates; protects the first 0.04 µm final-filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates, including mycoplasma-sized organisms (0.2–0.3 µm), that pass through a standard 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   A second, dedicated 0.1 µm prefilter protecting the second 0.04 µm final-filter cartridge — full redundancy, not a repeat pass on the same effluent.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate 0.04 µm polishing filter; aseptic fill & finish in an ISO Class 5 (Class 100) laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid is validated for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

A separate MPS Grade variant of this formulation, ultra nano-filtered to a 0.01 µm (10 nm) final cut-off through an extended six-stage cascade, is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 0.01 µm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the MPS Grade 0.01 µm variant.

Lot-release quality parameters

Every production batch of FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid undergoes the complete quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification. Total: 28 components across 4 categories (Inorganic Salts, Amino Acids, Vitamins, Others). Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-MEM-PRN1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o Sodium Pyruvate, Phenol Red: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
5. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
6. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
7. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
8. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175